Abstract: A multi electrode and needle injection device for identifying and treating muscle pain using two simultaneous electrode EMG recordings to locate an active trigger point. The two electrodes are displaced so that one electrode detects EMG activity at the trigger point and the other detects EMG activity adjacent to the trigger point, within the same muscle. The combination of the electrodes with a drug delivery system allows the user to inject a medication locally at the trigger point to block the trigger point activity and reduce or eliminate muscle pain. The electrodes are on a hypodermic needle. The needle is used to both facilitate the location of the trigger points, and for treatment, by injecting a drug into the trigger points.
Abstract: The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.
Abstract: Methods for treating non-insulin-taking Type II diabetes mellitus which comprise administering a therapeutically effective amount of an amylin agonist.
Type:
Grant
Filed:
November 6, 2000
Date of Patent:
July 9, 2002
Assignee:
Amylin Pharmaceuticals, Inc.
Inventors:
Orville G. Kolterman, Robert G. Thompson, John F. Mullane
Abstract: The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.
Type:
Grant
Filed:
January 9, 1998
Date of Patent:
June 25, 2002
Assignee:
Amylin Pharmaceuticals, Inc.
Inventors:
James L'Italien, Shankar Musunuri, Kale Ruby